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Abstract: Lipofilling has regenerative properties used to improve deformities after breast conserving 
surgery. Our hypothesis is that there is inadequate data to ensure that lipofilling does not increase 
locoregional cancer recurrence after breast conserving surgery. A PRISMA comprehensive literature 
review was conducted of articles published prior to October 2019 investigating recurrence in patients who 
underwent lipofilling after breast conserving surgery. All forms of breast conserving surgery, fat grafting, and 
injection intervals were included. Patients undergoing mastectomy were excluded. Requirements to define 
lipofilling as “safe” included (I) a defined interval between resection and lipofilling; (II) a minimum follow-
up period of 6 years from tumor resection; (III) a minimum follow-up period of 3 years from lipofilling; (IV) 
presence of a control group; (V) controls matched for ER/PR/Her-2; (VI) a sub-group analysis focusing on 
ER/PR/Her-2; (VII) adequate powering. Nineteen studies met inclusion criteria. The range in time from 
breast conserving surgery to fat injection was 0–76 months. The average time to follow-up after lipofilling 
was 23 days–60 months. Two studies had a sufficient follow-up time from both primary resection and from 
lipofilling. Seventeen of the nineteen studies specified the interval between resection and lipofilling, but there 
is currently no consensus regarding how soon lipofilling can be performed following BCS. Eight studies 
performed a subgroup analysis in cases of recurrence and found recurrence after lipofilling was associated 
with number of positive axillary nodes, intraepithelial neoplasia, high grade histology, Luminal A subtype, 
age <50, Ki-67 expression, and lipofilling within 3 months of primary resection. Of the eleven studies 
that included a comparison group, one matched patient for Her-2 and there was a statistically significant 
difference in Her-2 positive cancers in the study arms of two articles. Several studies deemed lipofilling “safe,” 
two showed association of lipofilling and local recurrence, and most studies concluded that further research 
was needed. Insufficient and contradictory data exists to demonstrate the safety of lipofilling after breast 
conserving surgery. A multicentered, well designed study is needed to verify the safety of this practice.
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Introduction
Breast conservation surgery (BCS) continues to be the 
most popular form of breast cancer surgery (1). As the 
indications for BCS continue to expand, there has been 
increased interest in personalized techniques of breast 
reconstruction (2). First introduced by Bircoll et al. in 
1987, lipofilling, or autologous fat grafting, is a technique in 
which a patient’s fat is harvested and centrifuged to obtain 
a concentrate rich in stem cells which is then transferred to 
the breast (3). With its advantages that include improved 
aesthetics in the area of the partial mastectomy, this 
technique is gaining increased use in BCS without clear 
consensus in this technique’s oncologic safety. Multiple 
in vitro studies have conjectured that adipocytes, 
preadipocytes, and their products may play a role in tumor 
recurrence as they are involved in the tumor cell cycle 
through autocrine, paracrine, and exocrine/endocrine 
secretions (4,5). Moreover, a review article published by 
Lohsiriwat et al. proposed that a “tumor-stroma interaction” 
can potentially induce cancer reappearance by “fueling” 
dormant breast cancer cells in the tumor bed (6). This 
would be particularly concerning if it were to occur at a 
positive tumor margin after BCS. 
In 2009, the American Society of Plastic Surgeons 
(ASPS) established a task force to assess the indications, 
safety and efficacy of lipofilling and concluded that, due 
to the limited data, they could not suggest evidence based 
recommendations concerning cancer recurrence (7). Few 
studies have focused on the oncological safety of lipofilling 
after BCS (8-10). Petit et al. reported the first case-matched 
retrospective series, which found no significant difference 
in local events (local relapse, locoregional relapse, or local 
relapse with synchronous metastases) between patients who 
underwent lipofilling after BCS and those who underwent 
BCS alone (10). Similarly, Gale et al. conducted a case-
matched retrospective series comparing oncological 
outcomes between 211 patients who underwent lipofilling 
after BCS with control patients matched for five variables 
and found no significant association between lipofilling 
and disease recurrence, both locoregional and distant (11). 
However, in 2013, Krastev et al. performed a systematic 
review and found marked increase in locoregional 
recurrence in patients who underwent lipofilling after 
BCS when compared to a large series of women treated 
with BCS (12). Despite the merits of these and other 
studies found in the literature, the lack of stratification of 
recurrence rate by tumor subtype, tumor stage, receptor 
status, and time to follow-up potentially limit their utility 
and applicability. The purpose of this project is to conduct a 
literature review utilizing PRISMA guidelines to investigate 
whether sufficient data exists to determine whether 
lipofilling following BCS increases the rate of locoregional 
tumor recurrence (LRR).
Methods
A systematic, online literature search was conducted 
following PRISMA guidelines (Figure 1). PubMed and 
MEDLINE were utilized to identify articles that investigated 
or commented on the oncological safety of lipofilling 
following BCS up until October 2019. Keywords included: 
“breast conserving surgery,” “lumpectomy,” “partial 
mastectomy,” “lipofilling,” “fat transfer,” “fat grafting,” 
“recurrence,” and “safety”. Oncoplastic surgery is a form 
of BCS (13,14) and was included in our definition of BCS. 
Ninety-three articles were initially identified. The citations 
of the 7 review articles/meta-analyses acquired from our 
search were screened to identify 6 additional articles. Fifty-
four unique articles remained after removing duplicates. 
Articles met inclusion criteria if (I) the study participants 
underwent lipofilling following BCS and (II) the authors 
reported the recurrence rate. Exclusion criteria included (I) 
mastectomy or other types of surgery without any patients 
undergoing BCS prior to lipofilling; (II) non-cancer related 
reconstruction; (III) in vitro and animal studies; (IV) review 
articles and meta-analyses; (V) correspondence/commentary; 
(VI) full text unavailable; (VII) languages other than English 
without an available translation. Nineteen articles satisfied 
inclusion and exclusion criteria.
After excluding ineligible publications, nineteen articles 
underwent full-text analysis by two independent reviewers 
(SMC, YS) to extract information regarding the number 
of patients that specifically underwent BCS, average time 
to follow-up from lipofilling, the interval between primary 
resection and lipofilling, presence of a subgroup analysis 
for ER/PR/HER-2 status to determine if there was an 
association with recurrence, if the study design included 
a control, if the control was matched for ER/PR/Her-2, 
commentary on adequate powering, recurrence rates, 
statement of oncologic safety, and call for additional 
studies/trials. Lipofilling was considered “safe” if there was 
(I) a description of the interval between cancer resection 
and lipofilling; (II) a minimum follow-up period of 6 years 
after primary cancer resection; (III) a minimum follow-up 
period of 3 years after lipofilling; (IV) an analysis of breast 
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cancer sub-groups specifically focusing on ER/PR/Her2; (V) 
a defined cohort comparison group; (VI) controls matched 
for receptor status; (VII) adequate powering. 
The interval between the primary oncologic surgery 
and lipofilling needed to be defined, as immediate 
lipofilling poses the risk of having positive margins prior to 
transferring stem cells, and adequate time may be required 
to ensure there is no recurrence before introduction 
of these autologous cells. A follow-up time of 6 years 
from primary resection and 3 years from lipofilling was 
requisite to conclude whether lipofilling is safe since most 
locoregional recurrences occur between 3–6 years following 
BCS (15,16). In addition, the ACOSOG Z0011 trial, which 
dramatically impacted the management of patients with 
axillary metastases, required a median time to follow-up of 
6 years (17). It is critical to match for receptor status in a 
cohort study design. A sub-group analysis of receptor status 
and outcome after lipofilling is needed as specific types of 
cancers have different tendencies to recur (18). 
Results
Study selection
Nineteen studies satisfied inclusion and exclusion criteria 
(Figure 1). Of the nineteen, none of the studies satisfied all 
7 criteria required to conclude that fat grafting after BCS is 
safe (Figure 2). 
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Figure 1 PRISMA methodology schematic.
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Participants
The number of patients who underwent lipofilling following 
BCS ranged from 7–143 patients (Table 1). Krastev et al. 
found that 13 patients were diagnosed with a second primary 
tumor in the contralateral breast during oncologic follow-
up and underwent additional lipofilling following tumor 
resection. Ipsilateral recurrence between primary resection 
and lipofilling was intended to be a contraindication to 
lipofill in groups not investigating the role of “immediate” 
lipofilling, however, but one patient in the study performed 
by Brenelli et al. experienced a locoregional recurrence and 
underwent subsequent lipofilling (19).
Study characteristics
Four retrospective case series, six prospective case series, 
six retrospective case control studies, and three prospective 
case control studies were included (Table 1).
Comparison group
Eleven studies included a comparison group (Table 2). 
Eight of the eleven studies were case control studies and 
three were retrospective case series in which patients 
who underwent BCS without lipofilling during the same 
time period at the same institution were selected as the 
comparison group without matching for any patient 
characteristics (Table 3). Three studies matched patients for 
ER receptor status alone (10,11,20), two studies matched 
patients for both ER and PR (21,22), and one study by 
Sorrentino et al. matched patients for Luminal A subtype, 
Luminal B subtype, and Triple Negative disease (23).
Sorrentino et al. performed a sub-analysis examining fat 
grafting and locoregional recurrence and distant metastases 
showed no increase in rate of recurrence during follow-up. 
However, their predictive model demonstrates that after 
80 months, there would be a statistically significant greater 
recurrence rate in patients with Luminal A cancers that 
Description of 
interval to fat 
injection
Time to 
follow-up 
from BCS
Time to 
follow-up  
from 
lipofilling
Subgroup 
analysis
Comparison 
group
Appropriately 
matched 
controls
Powering
Biasio et al.
Biazus et al.
Brenelli et al.
Debald et al.
Gale et al.
Garcia et al.
Kahn et al.
Krastev et al.
Mazur et al.
Mestack et al.
Perez-Cano et al.
Petit, Botteri et al.
Petit, Lohsiriwat et al.
Petit, Rietjens et al.
Reitjens et al.
Silva et al.
Sorrentino et al.
Silva et al. 
Stumpf et al.
Figure 2 Graphic representation of required criteria to establish safety of lipofilling following BCS. Criteria to determine safety of 
lipofilling following BCS included: (I) description of the interval between BCS and lipofilling; (II) time to follow-up from BCS of 6 years; (III) 
time to follow-up from lipofilling of 3 years; (IV) subgroup analysis focusing on ER, PR, Her-2; (V) presence of any comparison group at all; 
(VI) comparison group matched controls specifically for ER, PR, and Her-2; (VII) adequate powering. BCS, breast conservation surgery.
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underwent lipofilling compared to the matched control 
Luminal A cancers that did not undergo lipofilling (23). 
There was a statistically significant difference in Her-2 
expression between study arms in two studies: Silva 
et al. 2017 included 19.5% Her-2 positive in the lipofilling 
group vs. 28% in the control group (P=0.022) (20); Gale 
et al. included 15% Her-2 positive in the lipofilling group 
vs. 7.3% in the control group (P=0.013), but 37% of 
patients in the lipofilling group and 52.4% of patients 
in the control group had an unknown Her-2 status (11). 
There was equal representation of triple negative disease, 
ER, PR, and HER-2 expression in the experimental 
arms inclusive of both BCS and mastectomy without 
stratification for BCS alone in the study performed by 
Krastev et al. (24).
Time intervals
Seventeen of the nineteen studies specified the interval 
between BCS and lipofilling. Five studies evaluated safety 
after immediate lipofilling, lipofilling performed during 
the same operative time as the primary resection (Table 2). 
There were two articles that mandated that patients were 
cancer free for 12 months after primary cancer surgery as a 
part of their inclusion criteria, but they did not specify the 
actual interval between surgery and fat injection (25,26). 
The overall average range in time from primary surgery 
to fat injection ranged from 0–76 months. The average time 
to follow-up after lipofilling to assess for recurrence ranged 
from 23 days–60 months.
Eight studies out of nineteen had a three year time-
Table 1 Study design and rates of locoregional recurrence (LRR)
Study Design BCS + lipofilling (n) BCS alone (n) LRR BCS + lipofilling (%) LRR BCS alone (%)
Biasio et al. RCS 37 88 0 n/a
Biazus et al. PCS 65 0 7.86 n/a
Brenelli et al. PCS 59 patients (75 cases) 0 5.1* n/a
Debald et al. RCS 17 0 0 n/a
Gale et al. RCC 35 64 5.7 3.1
Garcia et al. PCS 37 0 0 n/a
Kahn et al. PCS 32 39 0 0
Krastev et al. RCC 139 150 0.72 4.7
Mazur et al. PCC 7 28 3.7** 4.1**
Mestack et al. RCC 32 45 0 4.4
Perez-Cano et al. PCS 67 0 0 n/a
Petit, Botteri et al. RCC 125 250 1.0 4.0
Petit, Lohsiriwat et al. RCS 143 patients (170 cases) 0 0.8 n/a
Petit, Rietjens et al. RCC 59 118 0.18 0.3
Rietjens et al. PCS 77 0 0.01 n/a
Silva et al. RCS 63 0 3.2 n/a
Silva et al. PCC 58 124 1.7 2.4
Sorrentino et al. PCC 54 444 6.4** 5.0**
Stumpf et al. RCC 27 167 3.7 4.2
*, reported as % recurrence per patient enrolled; **, overall LRR, not stratified for only BCS (includes mastectomy). BCS, breast 
conservation surgery; RCS, retrospective case series; PCS, prospective case series; RCC, retrospective case control; PCC, prospective 
case control.
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to-follow-up after lipofilling (22-25,27-30), seven studies 
satisfied an average time to follow-up after BCS of at least six 
years (11,19-21,23,24,31). Krastev et al. and Sorrentino et al. 
satisfied both the time to follow-up from BCS and from 
lipofilling, Krastev et al. followed patients for an average 
of 9 years from BCS and 4.3 years from lipofilling (23,24). 
Sorrentino et al. followed patients for an average of 
6.2 years from BCS and 4.2 years from lipofilling (Figure 2). 
One of the subgroups within the Petit, Reitjens et al. 
study may also satisfy both criteria, as 36% of their study 
participants underwent lipofilling >36 months after primary 
cancer resection and the average time to follow-up after 
lipofilling was 38 months (22). 
None of the “immediate” lipofilling studies satisfied our 
required time to follow-up after primary cancer resection 
since there was no waiting period between resection and 
lipofilling. However, all of the immediate lipofilling studies 
with the exception of Garcia et al., satisfied a requisite 3-year 
follow-up time following fat grafting (32). Of the other 
Table 3 Matched variables in studies including a comparison group
Reference Matching criteria
Biasio et al. Unmatched controls
Gale et al. Date of primary surgery (within 2 years)
Age (within 5 years)
Type of surgery (BCS vs. mastectomy)
Histology
ER status
Disease free interval before fat grafting
Kahn et al. Unmatched controls
Krastev et al. Age
Type of surgery (BCS vs. mastectomy)
Tumor invasiveness
Disease stage
Disease free interval before fat grafting
Mazur et al. Year of admission to a single institution
Age
Histology
Mestack et al. Date of primary surgery
Date of fat grafting
Histology
ER status 
PR status 
Adjuvant hormone therapy 
Disease free interval after primary surgery 
Disease free interval after fat grafting
Petit, Botteri et al. Age (within 5 years) 
Year of surgery (within 2 years)
Type of surgery (BCS vs. mastectomy) 
Histology 
Tumor size (T1/2/3) 
ER status
Table 3 (continued)
Table 3 (continued)
Reference Matching criteria
Petit, Rietjens et al. Age (within 5 years) 
Year of surgery (within 2 years) 
Type of surgery (BCS vs. mastectomy) 
histology
ER status 
PR status margin status 
Hormonal therapy 
Radiotherapy 
Disease free interval after primary surgery
Silva et al. 2017 Age (within 5 years) 
Year of surgery (within 3 years) 
Type of surgery (BCS vs. mastectomy),
 Histology
Lymphatic involvement 
ER status
Sorrentino et al. Age 
Histopathology 
Stage 
Luminal A (ER+ PR+ HER2−) 
Luminal B (ER+ PR+ HER2−) 
Triple negative
Stumpf et al. Unmatched controls
BCS, breast conservation surgery.
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immediate lipofilling studies, Biasio, Biazus et al., Kahn 
et al., and Stumpf et al. had a time to follow-up from the 
BCS and immediate lipofilling of 36, 40, 36 and 34 months 
respectively (27-29,33).
Sub-group analysis for receptor status
Eight studies reported the ER/PR/Her-2 status of cases 
of locoregional recurrence as a part of their subgroup 
analysis (Figure 2). Only one looked at Her-2 enriched and 
triple negative disease (23). Sorrentino et al. did not find a 
statistically significant difference in LRR upon subgroup 
analysis for Luminal A, Luminal B, Her-2 enriched, or 
Triple Negative disease in lipofilling compared to control 
groups. However, their logistic regression model found a 
statistically significant difference in locoregional recurrence 
after 80 months for Luminal-A subtype. This analysis was 
not restricted to BCS and included patients undergoing 
mastectomy.
Recurrence
Petit, Reitjens et al. demonstrated a significant difference 
in the locoregional recurrence rates between patients 
undergoing lipofilling after BCS compared to BCS alone, 
0.18% and 0.03% respectively (Table 1). Five studies 
reported a locoregional recurrence rate of 0% in the fat 
grafting group. Krastev et al. and Sorrentino et al. found that 
there was a higher rate of locoregional recurrence in the 
control group than the fat grafting group after BCS (Table 1), 
but that the difference was not significant. Krastev et al. 
found a statically significant difference in overall mortality 
in the control group compared lipofilling group in all forms 
of surgery (both mastectomy and BCS) of 11.0% in the 
control group compared to 2.6% in the lipofilling group 
(P<0.001). This difference persisted when the analysis was 
restricted to breast cancer-specific mortality (24).
Statement of oncological safety
Fifteen papers determined that further investigation is 
required to determine if there is an association between 
lipofilling after BCS and recurrence. Five articles stated that 
it is unclear whether or not lipofilling is safe. There were 
seven studies that simultaneously declared that there was a 
need for further investigation but endorsed that lipofilling 
is “safe” (20,21,25,26,30,31,33). Four utilized ambiguous 
verbiage such as “seems to be safe,” or “interpret with 
other similar case-controlled studies” (10,11,27,28). Petit, 
Rietjens and Botteri concluded that there is an increased 
risk in certain groups and that lipofilling may be unsafe for 
those patients (22). 
Statistical power
None of the studies quantified the statistical power of their 
analyses.
Risk factors for recurrence
Biazus, Stumpf, Melo et al. performed a subgroup analysis 
that demonstrated that the number of metastatic axillary 
lymph nodes was associated with increased recurrence 
after lipofilling (28). Petit, Botteri, Lohsiriwat et al. found 
a higher risk of recurrence in patients with intraepithelial 
neoplasia and not invasive disease (10). Petit, Rietjens, and 
Botteri found that Ki-67 expression, age <50, and high-
grade neoplasia were associated with increased rates of 
recurrence (22). Silva-Vergara, Fontdevila et al. found that 
there was an increased risk of recurrence if lipofilling was 
performed within 3 months of primary resection (20). 
Krastev et al. found no significant difference in local 
recurrence rates based on receptor subtype or if the 
injection interval was <5 years from primary resection to 
lipofilling (24).
Sorrentino et al. did not find that there was a statistically 
significant increase in LRR based on tumor subtype during 
their time to follow-up but their logistic regression model 
found a statistically significant difference in locoregional 
recurrence after 80 months for patients with Luminal A 
type cancer. 
Discussion
The importance of this study cannot be understated. 
Lipofilling in the setting of breast conservation is presently 
being done and the data presented here shows, at best, 
that the oncologic safety supporting this technique in this 
population of patients is unclear. Surgeons and their patients 
performing this type of reconstruction need to know the 
potential unclear implications of injecting stem cells into 
a breast defect that has had a history of cancer present. 
Several studies have attempted to address the safety of 
lipofilling, with some confusingly concluding that lipofilling 
is safe yet still proceeding to recommend for future studies 
to investigate for safety (20,21,23,25,26,29,30). Our criteria 
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for safety was adopted from past studies that addressed 
oncologic safety based on interventions performed. With 
regards to our first criteria, seventeen of the nineteen 
studies specified the average time interval between resection 
and lipofilling. Average values reflect a range of time 
intervals, raising the possibility that some study participants 
had adequate time (>6 years) to follow-up from primary 
surgery while others did not. The wide ranges in injection 
intervals between studies demonstrates a lack of consensus 
for a “safe” time of injection. It can be argued that the 
time to injection may affect the response of local cells to 
the stem cell effect of fat being injected. Silva-Vergara 
et al. demonstrated that there was an increased risk of 
recurrence if lipofilling occurred within three months after 
partial mastectomy (30). On the other hand, Krastev et al. 
found that there was not an increased risk of recurrence 
when injection intervals were <5 years (24) and Sorrentino 
et al. found early fat grafting was not associated statistically 
significant increased rates of recurrence despite finding 
that there was a higher proportion of early fat grafting 
among recurrent patients (23). Brenelli et al. reported a 
locoregional recurrence risk of 5.1% and only included 
3 patients of the 59 that underwent lipofilling following 
BCS in their locoregional recurrence calculation rather 
than the 4 that experienced a recurrence since one patient 
actually had a histologically confirmed tumor recurrence in 
the interval prior to lipofilling (24).
Immediately injecting fat into a partial mastectomy 
cavity without proven negative margins could be dangerous 
if a positive margin would receive stem cells from injected 
fat. There have been retrospective studies that have injected 
fat into partial mastectomy defects at the same time of 
oncologic resection which is not recommended by the 
authors without clear future prospective randomized data 
and patient-informed consent proving safety (28,29,32,33). 
Krastev et al. and Sorrentino et al. were the only groups 
that employed an experimental design with an adequate 
time to follow-up from BCS and from lipofilling, but their 
methodology and results were still imperfect and plagued 
with design flaws that shall be discussed (23,24).
 Locoregional recurrence was studied in all included 
articles, but a majority of studies underpowered their 
comparison groups, especially since the number of subjects 
became too few if breast cancers were separated into 
their molecular subtypes (based on the ER, PR and Her2 
status). Of the 11 studies that had a comparison group, only 
3 studies matched patients based on both ER and PR status 
(21,22). Krastev et al. did attempt to investigate the role 
of hormone receptor status and triple negative disease and 
found no significant difference in locoregional recurrence 
between lipofilling and control groups (24). However, this 
study mixed mastectomy patients with breast conservation 
patients when looking at molecular subtypes between the 
lipofilling and control groups. Sorrentino et al. matched 
study participants by breast cancer subtype: Luminal A, 
Luminal B, Her-2 enriched, and Triple Negative disease. 
However, they did not match patients for the type of 
surgery performed. In fact, mastectomy accounted for 
76.8% of lipofilling arm whereas only 25.6% of the controls 
underwent mastectomy and the remainder underwent 
BCS. Given this mixture of mastectomy and BCS patient 
sampling, even though they did perform a sub-group 
analysis, one cannot say with statistical certainty that 
receptor status does not impact recurrence after BCS when 
cancerous cells may still persist in the tumor cavity.
Without adequate powering for the different molecular 
subtype presentations between the lipofilling and control 
groups specifically undergoing BCS, a Type II statistical 
error is possible showing no statistical difference between 
the lipofilling and no lipofilling arms when in fact there 
may be, as chance plays a large role in the conclusion. To 
date, there is no study with confirmed, adequate powering 
looking at lipofilling after breast conservation when 
separating breast cancers into their molecular subtypes. 
Although Krastev et al. did not find a difference in 
locoregional recurrence in the cases of lipofilling after BCS, 
the overall mortality for patients undergoing both BCS and 
mastectomy without lipofilling was 11.0% while the overall 
mortality in lipofilling group was 2.6%. This recurrence 
rate is high considering they did not enroll any patients 
with stage IV disease, and the majority of their patients 
had either stage 0 or early stage disease. The 5-year breast 
cancer specific survival for stage 1 disease has been noted to 
be between 98–100% according to the literature (34). Thus, 
it is highly unlikely that fat grafting lead to a more favorable 
prognosis and further investigation into pre-selection biases 
or confounding variables is critical. In contradiction, Petit 
et al. found that lipofilling was associated with an increase of 
local recurrence when intraepithelial neoplasia (e.g., DCIS) 
was present as opposed to invasive disease (10). 
There have been transitional studies utilizing animal 
models to explore the safety of lipofilling which also have 
had mixed conclusions (35,36). Tsuji et al. and Silva et al. 
both utilized “immortal” cell lines injected into rats to 
simulate a tumor bed prior to fat transfer. They found 
that autologous fat transfer did not encourage tumor 
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growth, and may actually suppress tumor cell proliferation. 
However, clonal cell lines do not reproduce the tumor 
heterogeneity that is present in vivo, and surgery was not 
performed in either study. In fact, Silva et al. suggested that 
mechanical pressure of the adipose cells injected adjacent to 
the tumors may have impaired tumor cell proliferation. 
In vitro models have associated fat grafting with 
increased tumor growth. Almarzougi et al. examined the 
role of lipoaspirates and resected abdominal fat on tumor 
cells and found that adipose increases the proliferation of 
MCF-7 (ER/PR positive, luminal type) cells, contrary to 
the findings in the Tsuji et al. animal model (37). Moreover, 
Massa et al. demonstrated that adipose fat grafts could 
accelerate development a subclinical tumor or support 
locoregional recurrence of a previous tumor (38). 
Historically, past surgical interventions were studied 
using strict experimental design requirements (17,39,40) 
that are absent from the studies so far that have investigated 
lipofilling. The authors submit that the same rigor of 
experimental design that would include appropriate 
molecular subtype analysis with adequate powering, an 
established follow-up period, and an ethical, informed 
consent process given prospectively to the patient should 
be required before declaring lipofilling as safe in breast 
conservation. Fat grafting may be useful in certain clinical 
scenarios, but if it was found to be harmful in partial 
mastectomy defect corrections, it is possible that there 
could be subsequent reactionary regulations limiting the 
ability to fat graft in all facets of reconstruction. 
The data supporting the “safety” of lipofilling in breast 
conservation so far are incomplete; thus, one cannot state that 
lipofilling in breast conservation is safe. At best, these results 
show that the safety of lipofilling in breast conservation is 
unclear with contradictory data present in the literature. 
Surgeons with interest in fat grafting and lipofilling need 
to be cautious and inform their patients requesting these 
interventions of these uncertainties regarding loco-regional 
recurrences. Central to our Hippocratic Oath is to do no 
harm and with this, regardless of how nicely lipofilling 
corrects poor aesthetics after partial mastectomy, form can 
never trump oncologic safety. In a perfect world, there is a 
need for prospective studies with adequately powered cohort 
control groups looking at molecular subtypes and initiating 
lipofilling treatments at appropriate time intervals after 
margins are clear with appropriate post-operative follow-up 
in order to prioritize patient safety.
Conclusions
Present studies looking at lipofilling in the setting of 
breast conservation have several design limitations and 
do not prove oncologic safety. A well designed, ethical, 
appropriately powered, prospective study with comparison 
groups looking at molecular subtypes needs to be performed 
to ensure patient safety before surgeons consider treating 
breast conservation defects with lipofilling.
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